SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantirs rally to fresh highs is being tied to bullish analyst upgrades, especially Goldman Sachs Buy call citing sovereign AI demand and customized software opportunities. Bulls are celebrating the breakout and speculating about a short squeeze, while skeptics argue the valuation is stretched and warn of a pullback.

Snowflake, Inc. engages in the provision of cloud data warehousing software. The firm offers Data Cloud, an ecosystem where Snowflake customers, partners, data providers, and data consumers can break down data silos and derive value from data. Its platform supports a range of use cases including data warehousing, data lakes, data engineering, data science, data application development, and data sharing. The cloud-native architecture consists of layers across storage, compute, and cloud services. The storage layer ingests structured and semi-structured data to create a unified data record. The compute layer provides dedicated resources to enable users to access common data sets for many use cases without latency. The cloud services layer optimizes each use case's performance requirements with no administration. The company was founded by Marcin Zukowski, Thierry Cruanes, and Benoit Dageville on July 23, 2012 and is headquartered in Menlo Park, CA.

Snowflake Inc

Snowflakes launch of Agentic Marketplace Discovery is drawing attention as traders connect the product to continued AI demand and a broader rotation into software stocks. Bulls see a breakout, while skeptics point to the stocks high valuation and lack of GAAP profitability.

AST SpaceMobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an intellectual property and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

SpaceXs agreement to acquire Grain Managements low-band spectrum has intensified concerns that it could compete with AST SpaceMobile, contributing to a sharp selloff. Traders are split between viewing the deal as a threat and seeing ASTSs carrier partnerships and access to partner spectrum as a buffer or potential advantage.

T-Mobile US, Inc. engages in the provision of wireless communications services under the T-Mobile and MetroPCS brands. It offers postpaid and prepaid wireless voice, messaging and data services, and wholesale wireless services. The company was founded in 1994 and is headquartered in Bellevue, WA.

T-Mobile US Inc

SpaceXs agreement to acquire low-band spectrum for Starlink Mobile has raised concerns that it could eventually compete with T-Mobile and other U.S. wireless carriers, prompting a sharp selloff. Traders are divided between viewing the move as a long-term competitive threat and calling the reaction excessive, since building a rival network would require substantial infrastructure and time.

Nasdaq, Inc. is a holding company, which engages in trading, clearing, exchange technology, regulatory, securities listing, information, and public and private company services. It operates through the following segments: Capital Access Platforms, Financial Technology, and Market Services. The Capital Access Platforms segment delivers liquidity, transparency, and integrity to the corporate issuer and investment community by empowering clients to effectively navigate the capital markets, achieve their sustainability goals, and drive governance excellence. The Financial Technology segment offers platforms that improve the liquidity, transparency, and integrity of the global economy by architecting and operating the markets. The Market Services segment includes equity derivative trading and clearing, cash equity trading, fixed income, currency, and commodities trading. The company was founded by Gordon S. Macklin in 1971 and is headquartered in New York, NY.

Nasdaq Inc

Nasdaqs planned move to 23-hour weekday trading is driving discussion alongside broader interest in 24/7 markets and tokenized equities. Traders see expanded access as a potential boost for exchanges, while others question whether overnight trading will bring enough liquidity or add volatility.

Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Branded and ImprimisRx. The Branded segment includes activities of the company’s FDA approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain branded products. The ImprimisRx segment represents activities in the company’s ophthalmology-focused pharmaceutical compounding business. The company was founded by Mark L. Baum and Robert J. Kammer on January 11, 2006 and is headquartered in Nashville, TN.

Harrow Inc

Harrow Health Inc

Harrow is under pressure amid speculation that investor Opaleye may be selling down or unwinding its stake, though traders say the extent of any sales is unclear. The discussion also centers on upcoming Q3 revenue and whether VEVYE growth can translate into stronger revenue and EBITDA after repeated guidance and execution concerns.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

A sharp rebound from months of choppy trading has put Hims & Hers back in focus, with traders pointing to a possible technical breakout and speculating about short covering. Some also cite potential peptide access as an upside catalyst, but that remains speculation; others warn the rally may fade at resistance.

Sea Ltd. is an internet and mobile platform company, which engages in the provision of online gaming services. It operates through the following segments: Digital Entertainment, E-Commerce, and Digital Financial Services. The Digital Entertainment segment offers and develops mobile and PC online games. The E-Commerce segment manages a third-party marketplace through the Shopee mobile app and websites that connect buyers and sellers. The Digital Financial Services segment includes a variety of payment services and loans to individuals and businesses through SeaMoney. Sea was founded by Xiao Dong Li, Gang Ye, and Jing Ye Chen on May 8, 2009 and is headquartered in Singapore.

Sea Ltd - ADR

Seas sharp pullback and volatile rebound are driving debate: bearish traders point to insider sales, weak price action and macro headwinds, while bulls argue its strong e-commerce and fintech growth makes the shares undervalued. The prior quarters strong revenue growth and Shopee profitability outlook support the bullish case, though some traders remain wary of the earnings-per-share miss and continued selling pressure.

Verizon Communications, Inc. is a holding company, which engages in the provision of communications, information, and entertainment products and services. It operates through the following business segments: Consumer and Business. The Consumer segment provides consumer-focused wireless and wire line communications services and products. The Business segment offers wireless and wireline communications services and products, including FWA broadband, data, video and conferencing services, corporate networking solutions, security and managed network services, local and long-distance voice services, and network access to deliver various IoT services and products. The company was founded in 1983 and is headquartered in New York, NY.

Verizon Communications Inc

Verizon Communications Inc.

SpaceXs agreement to acquire low-band spectrum for Starlink Mobile has raised fears that it could eventually compete with Verizon and other U.S. wireless carriers, weighing on VZ shares. Traders are divided between viewing the move as a serious long-term threat and calling the selloff an overreaction given the time, investment and infrastructure needed to build a competitive network; many are treating the drop as a buying opportunity.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trumps reported agreement to bring Russian diesel into the U.S. amid the Iran conflict dominates discussion, with many traders criticizing it as easing pressure on Moscow and undermining Ukraine while others defend it as a way to address fuel costs. The debate also reflects concern over the wars impact on energy prices and the administrations political prospects.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Aarti Pharmalabs Gets 1 Observation in USFDA Inspection at Tarapur Unit

Mumbai: Aarti Pharmalabs Limited has successfully completed an inspection … any significant compliance issues. Aarti Pharmalabs further stated that it will … the stipulated timeline. Also Read: Aarti Drugs gets USFDA EIR for Tarapur …

Brief India: Signature Global Ltd - Q3FY26: Slow Quarter; Entering Phase of Steady Growth and more

In this briefing: Signature Global Ltd - Q3FY26: Slow Quarter; Entering Phase of Steady Growth Westlife Foodworld Ltd - Demand Recovery Brewing; Margins Stay Strong JK Lakshmi Cement Limited - Lower Realisation Impacted Performance; Retain BUY Trent Ltd - Short-Term Noise, Long-Term Story Intact; Maintain BUY Aarti Drugs Ltd - Operational Headwinds Cloud Q3FY26 1. Signature Global Ltd - Q3FY26: Slow Quarter; Entering Phase of Steady Growth Maturing Gurugram Micro-Markets: Signature Global’s portfolio remains heavily concentrated in the micro-markets of Gurugram. Housing demand in Gurugram is transitioning from a fast, hype-driven phase to a more stable, end-user-led market. As a result, the company’s annual pre-sales are likely to normalise at around ~Rs 10,000 Cr, with price growth moderating to gradual high single digits. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only.

Brief India: Westlife Foodworld Ltd - Demand Recovery Brewing; Margins Stay Strong and more

In this briefing: Westlife Foodworld Ltd - Demand Recovery Brewing; Margins Stay Strong JK Lakshmi Cement Limited - Lower Realisation Impacted Performance; Retain BUY Trent Ltd - Short-Term Noise, Long-Term Story Intact; Maintain BUY Aarti Drugs Ltd - Operational Headwinds Cloud Q3FY26 India: Trade Agreements to Attract Foreign Investment 1. Westlife Foodworld Ltd - Demand Recovery Brewing; Margins Stay Strong Demand recovery combined with strong value strategy: The company is witnessing a clear improvement in guest counts from December onwards, with January trends continuing to remain positive. The Rs 99 value platform has now been rolled out across the West and select South markets without any adverse impact on gross margins, underscoring effective cost control. Management’s focus remains firmly on driving higher footfalls rather than only increasing ticket size, which is an appropriate strategy in a soft demand environment. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only.

Brief India: Trent Ltd - Short-Term Noise, Long-Term Story Intact; Maintain BUY and more

In this briefing: Trent Ltd - Short-Term Noise, Long-Term Story Intact; Maintain BUY Aarti Drugs Ltd - Operational Headwinds Cloud Q3FY26 India: Trade Agreements to Attract Foreign Investment India: EU FTA, US Tariff Reductions Dovetail with Budget's Manufacturing Focus Aequitas: Turtlemint Fintech Solutions Limited Pre-IPO Tearsheet 1. Trent Ltd - Short-Term Noise, Long-Term Story Intact; Maintain BUY Revenue Performance: Trent posted a 16% YoY revenue growth in Q3FY26, with sales reaching Rs 5,259 Cr. However, the early festive season and the transition to the revised GST structure impacted QoQ comparability. In the near term, consumers showed a preference for higher-value purchases that benefited more from GST reductions, though demand for lower-ticket discretionary categories is expected to normalise over the medium term. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only.

Brief Healthcare: Primer: HeXun Biosciences (6986 TT) - Nov 2025 and more

In this briefing: Primer: HeXun Biosciences (6986 TT) - Nov 2025 Classys (214150 KQ/Buy)Targeting Brazil with a Proven M&A Playbook Krishna Institute of Medical Sciences Ltd - Expansion-Led Growth Continues... Aarti Drugs Ltd - Capacity Ramp-Up and Margin Gains Fuel Performance Global Health Ltd - Strengthening Network with Noida Launch 1. Primer: HeXun Biosciences (6986 TT) - Nov 2025 HeXun Biosciences operates a unique and synergistic dual-strategy business model, leveraging stable cash flow from its Contract Development and Manufacturing Organization (CDMO) services to fund its in-house development of high-potential stem cell-based new drugs. The company is strategically positioned in the high-growth regenerative medicine and biologics markets, with a focus on mesenchymal stem cells (MSCs) for cardiovascular diseases, a leading cause of death globally. Recent financial performance demonstrates exceptional growth, with revenue increasing by 119.36% and net income by 339.62% in the most recent fiscal year, transitioning the company from a loss-making entity to a profitable one with strong margin expansion.

Brief Healthcare: Classys (214150 KQ/Buy)Targeting Brazil with a Proven M&A Playbook and more

In this briefing: Classys (214150 KQ/Buy)Targeting Brazil with a Proven M&A Playbook Krishna Institute of Medical Sciences Ltd - Expansion-Led Growth Continues... Aarti Drugs Ltd - Capacity Ramp-Up and Margin Gains Fuel Performance Global Health Ltd - Strengthening Network with Noida Launch Primer: Classys (214150 KS) - Nov 2025 1. Classys (214150 KQ/Buy)Targeting Brazil with a Proven M&A Playbook For 3Q25, Classys reported in-line revenue of W83bn (+40% YoY) and below-consensus operating profit of W37.6bn (+30% YoY; OP margin of 45.3%). By category, aesthetic device revenue grew 30% YoY to W42.9bn, consumables revenue expanded 46% YoY to W37.3bn, and other revenue surged 310% YoY to W2.7bn. By region, domestic revenue climbed 57% YoY to W29.8bn, and overseas revenue increased 32% YoY to W53bn. Excluding Brazil, overseas revenue expanded 80% YoY. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only.

Brief Healthcare: Krishna Institute of Medical Sciences Ltd - Expansion-Led Growth Continues... and more

In this briefing: Krishna Institute of Medical Sciences Ltd - Expansion-Led Growth Continues... Aarti Drugs Ltd - Capacity Ramp-Up and Margin Gains Fuel Performance Global Health Ltd - Strengthening Network with Noida Launch Primer: Classys (214150 KS) - Nov 2025 Canbas Co Ltd (4575 JP): Q1 FY 06/26 flash update 1. Krishna Institute of Medical Sciences Ltd - Expansion-Led Growth Continues... Revenue In Line; Profitability Impacted by New Units: KIMS reported revenue broadly in line with our estimates, while EBITDA and PAT came in below expectations due to the initial ramp-up of new hospitals and the resultant operating deleverage. Profitability was impacted by higher depreciation and interest costs associated with the new facilities introduced. Reported revenue stood at 961 Cr, with margins at 21.2%, impacted by the addition of new units. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only.

Brief Growth Ideas: VA Tech Wabag Ltd - Robust Orderbook Reassures Long-Term Growth; Maintain BUY and more

In this briefing: VA Tech Wabag Ltd - Robust Orderbook Reassures Long-Term Growth; Maintain BUY KPIT Technologies Ltd - Impact of Acquisition Spends; Significant Recovery from FY27 Embassy Office Parks REIT Ltd - Q2FY26: Expansion on Track; Healthy NOI Aarti Drugs Ltd - Capacity Ramp-Up and Margin Gains Fuel Performance Global Health Ltd - Strengthening Network with Noida Launch 1. VA Tech Wabag Ltd - Robust Orderbook Reassures Long-Term Growth; Maintain BUY Robust Execution and Order Pipeline to Fuel H2FY26 Growth: Wabag delivered a 19% YoY growth in revenue for Q2FY26, broadly meeting our estimates. Revenue recognition is typically skewed towards the second half of the year, indicating strong H2. The management mentioned that margins may vary on a quarterly basis, while the medium-term margin outlook remains intact. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only.

Brief Equities Bottom-Up: VA Tech Wabag Ltd - Robust Orderbook Reassures Long-Term Growth; Maintain BUY and more

Brief Equities Bottom-Up: KPIT Technologies Ltd - Impact of Acquisition Spends; Significant Recovery from FY27 and more

In this briefing: KPIT Technologies Ltd - Impact of Acquisition Spends; Significant Recovery from FY27 Embassy Office Parks REIT Ltd - Q2FY26: Expansion on Track; Healthy NOI Aarti Drugs Ltd - Capacity Ramp-Up and Margin Gains Fuel Performance Global Health Ltd - Strengthening Network with Noida Launch Calix’s Next Frontier: Can MDUs & International Push Boost Its Market Performance? 1. KPIT Technologies Ltd - Impact of Acquisition Spends; Significant Recovery from FY27 Macro Environment Outlook: The overall macro environment has shown a marked improvement, with uncertainty levels reducing by over 50% compared to Q4FY25. Europe displayed strong traction during the quarter as clients began transitioning their supply chains from local to more globally integrated ecosystems. Deal Wins/Pipeline: The company announced a major multi-year, multi-domain deal from a leading European OEM. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only.

Aarti Drugs Ltd. engages in the development, manufacture and market of pharmaceutical products. The firm operates through the Out of India, and India geographical segments. Its products include active pharmaceutical ingredient, specialty chemicals, pharma intermediate, products under development, and product under pipeline. The company was founded on September 28, 1984 and is headquartered in Mumbai, India.

Current Price	412.20
Prev Close	418.00
Open	415.00
Dividend Yield	N/A
50-Day Moving Average	422.71
Beta	-0.03
Avg. Volume	211,043.52
PE Ratio	19.73

52-Week High	534.00
52-Week Low	318.95
Market Capitalization	37.88B
EPS (Annual)	21.36
Price to Book	2.44
Revenue Per Employee	9.03M

Feed

News

Sentiment

Fundamentals

Info

AARTIDRUGS.NSE Fundamentals